Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | DRD2 | P14416 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513431 | 0.92 | CXCR4 (0.78) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2508668 | 0.92 | CXCR4 (0.80) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2513427 | 0.92 | CXCR4 (0.78) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2508662 | 0.92 | CXCR4 (0.80) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2526582 | 0.91 | CXCR4 (0.75) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL14131181 | 0.91 | CXCR4 (0.75) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2508580 | 0.90 | CXCR4 (0.77) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Bromide SCHEMBL5134127 | 0.90 | CXCR4 (0.74) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL14131218 | 0.89 | CXCR4 (0.73) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2510374 | 0.89 | CXCR4 (0.78) | CXCR4CHRM2CYP2D6DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020047410-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | X4 PHARMACEUTICALS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |